Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783132 | 0.92 | BRD4 (0.35) | BRD4CREBBPTNKSTNKS2PARP3 | |
| SCHEMBL7198398 | 0.92 | BRD4 (0.35) | BRD4CREBBPTNKSTNKS2PARP3 | |
| SCHEMBL7037709 | 0.90 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL7110783 | 0.88 | BRD4 (0.33) | BRD4CREBBP | |
| SCHEMBL3997088 | 0.87 | BRD4 (0.33) | BRD4CREBBP | |
| SCHEMBL7197984 | 0.86 | BRD4 (0.33) | BRD4CREBBP | |
| SCHEMBL4620494 | 0.84 | PDCD1 (0.33) | BRD4 | |
| SCHEMBL7035276 | 0.84 | BRD4 (0.33) | BRD4CREBBPNPC1LMNATP53 | |
| SCHEMBL7035813 | 0.84 | BRD4 (0.33) | BRD4CREBBPTNKSTNKS2PARP3 | |
| SCHEMBL6890554 | 0.83 | BRD4 (0.36) | BRD4CREBBPTNKSTNKS2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784305-B2 | DERIVATIVES OF ZIRCONOCENE DICHLORIDE IN WHICH THE TWO SUBSTITUTED INDENYL GROUPS ARE JOINED TO ONE ANOTHER VIA A BRIDGE CAN, OWING TO THEIR CONFORMATIONAL RIGIDITY, BE USED AS CATALYSTS FOR THE STEREOSPECIFIC POLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | EQUISTAR CHEMICALS, LP | 2003-10-23 | — | — | US | disclosed |
| US-6620953-B1 | Complexing dimethylbis(2-methyl-4,5-benzoindenyl)silane with transition metal compounds such as 2,4-di-tert-butylphenoxide, zirconium monochloride, to form polymerization catalysts | BASSELL POLYOLEFINE GMBH (DE) | 2003-09-16 | — | — | US | disclosed |
| EP-1133504-B1 | METHOD FOR PRODUCING MONOARYLOXY-ANSA-METALLOCENES | BASELL POLYOLEFINE GMBH (DE) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | ABL1, ICMT, ORAI2 | BRD4 64/4885CREBBP 2742/4885TNKS 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.